Cordlife Group Limited (CLIFF) Stock

About Cordlife Group Limited

As an investment holding company, Cordlife Group Limited offers cord blood banking solutions across various countries including Singapore, Hong Kong, India, Malaysia, and the Philippines, extending its reach globally. Its operations are structured into two distinct segments: Banking and Diagnostics. The Banking segment is dedicated to the processing and secure storage of stem cells derived from cord blood, cord lining, and cord tissue. Meanwhile, its Diagnostics arm delivers a suite of screening services, such as non-invasive prenatal testing, pediatric vision evaluations, and genetic and metabolic screenings for newborns. Furthermore, Cordlife extends its diagnostic offerings to include specialized procedures like preimplantation genetic screening, endometrial receptivity testing, pediatric allergen analysis, and genetic talent assessments. It also supports parents through "moms up," a mobile application providing valuable resources for pregnancy and parenting. Beyond its core medical services, the company engages in management, marketing, and property investment activities. Established in 2001, Cordlife Group Limited maintains its corporate headquarters in Singapore.

Cordlife Group Limited is headquartered in SG.

Cordlife Group Limited (CLIFF) stock trades at $0.09 with a market capitalization of $23.09M. The stock is valued at a price-to-earnings (P/E) ratio of -3.10, price-to-book of 0.35, price-to-sales of 0.99. Over the past 52 weeks the stock has ranged between $0.07 and $0.17, and currently trades 47.1% below its 52-week high.

On profitability, Cordlife Group Limited generates a return on equity (ROE) of -10.82%, return on capital employed of -7.67%, an operating margin of -35.85%, a net profit margin of -31.95%.

Official website: www.cordlife.com